Clinical Trial Update: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 study update assessing safety and biomarkers of resmetirom (MGL-3196) for non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Resmetirom (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 3 | Status: COMPLETED